Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial

Archives of Physical Medicine and Rehabilitation

Volumn 90, Issue 7, 2009, Pages 1094-1101

  Payan, C A ^a   Hogrel, J Y ^a   Hammouda, E H ^b   Lacomblez, L ^a   Ollivier, G ^a   Doppler, V ^a   Eymard, B ^a   Attarian, S ^c   Pouget, J ^c   Desnuelle, C ^d   Laforet P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Association Francaise Contre les Myopathies   (France)

^c TIMONE HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Clinical trial, Phase III; Facioscapulohumeral muscular dystrophy; Pharmacokinetics; Rehabilitation; Salbutamol

Indexed keywords

PLACEBO; SALBUTAMOL;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANUAL MUSCLE TESTING; MIGRAINE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MUSCLE FUNCTION; MUSCLE STRENGTH; PHASE 3 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; QUANTITATIVE MUSCLE TESTING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; TREATMENT DURATION; TREMOR; VERTIGO;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; YOUNG ADULT;

EID: 67649406068     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2008.12.027     Document Type: Article

References (26)

1. Padberg G.W. Facioscapulohumeral disease (1982), Leiden University, Leiden
2. van Deutekom J.C., Wijmenga C., van Tienhoven E.A., et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 2 (1993) 2037-2042
3. Martineau L., Horan M.A., Rothwell N.J., and Little R.A. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond) 83 5 (1992) 615-621
4. Yang Y.T., and McElligott M.A. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 261 (1989) 1-10
5. Maltin C.A., Delday M.I., Watson J.S., et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond) 84 6 (1993) 651-654
6. Collomp K., Candau R., Lasne F., Labsy Z., Prefaut C., and De Ceaurriz J. Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol 89 2 (2000) 430-436
7. Kissel J.T., McDermott M.P., Natarajan R., et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 50 5 (1998) 1402-1406
8. Kissel J.T., McDermott M.P., Mendell J.R., et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57 (2001) 1434-1440
9. van der Kooi E.L., Vogels O.J., van Asseldonk R.J., et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63 (2004) 702-708
10. Rothwell N.J., Stock M.J., and Sudera D.K. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br J Pharmacol 90 (1987) 601-607
11. Hogrel J.Y., Payan C.A., Ollivier G., et al. Development of a French isometric strength normative database for adults using quantitative muscle testing. Arch Phys Med Rehabil 88 (2007) 1289-1297
12. Duncan N.D., Williams D.A., and Lynch G.S. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond) 98 3 (2000) 339-347
13. Sykes R.S., Reese M.E., Meyer M.C., and Chubb J.M. Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Biopharm Drug Dispos 9 (1988) 551-556
14. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology 48 (1997) 38-46
15. Milroy R., Carter R., Carlyle D., and Boyd G. Clinical and pharmacological study of a novel controlled release preparation of salbutamol. Br J Clin Pharmacol 29 (1990) 578-580
16. Lipworth B.J., Clark R.A., Dhillon D.P., Charter M.K., Palmer J.B., and McDevitt D.G. Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. Eur J Clin Pharmacol 37 (1989) 49-52
17. Maesen F.P., and Smeets J.J. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur J Clin Pharmacol 31 (1986) 431-436
18. van der Kooi E.L., Kalkman J.S., Lindeman E., et al. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J Neurol 254 (2007) 931-940
19. Skura C.L., Fowler E.G., Wetzel G.T., Graves M., and Spencer M.J. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70 (2008) 137-143
20. Kinali M., Mercuri E., Main M., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 59 (2002) 609-610
21. Fowler E.G., Graves M.C., Wetzel G.T., and Spencer M.J. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62 (2004) 1006-1008
22. Messina S., Hartley L., Main M., et al. Pilot trial of salbutamol in central core and multi-minicore diseases. Neuropediatrics 35 5 (2004) 262-266
23. Dupont-Versteegden E.E., Katz M.S., and McCarter R.J. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve 18 (1995) 1447-1459
24. Escolar D.M., Buyse G., Henricson E., et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 58 (2005) 151-155
25. Vincent K.A., Carr A.J., Walburn J., Scott D.L., and Rose M.R. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 68 (2007) 1051-1057
26. Berard C., Payan C., Hodgkinson I., and Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 15 (2005) 463-470